These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24338577)

  • 1. Serum ischemia modified albumin and vascular endothelial growth factor levels following intravitreal bevacizumab injections.
    Soiberman U; Levy R; Schwartz S; Goldstein M; Loewenstein A; Barak A
    Eur J Ophthalmol; 2014; 24(4):570-5. PubMed ID: 24338577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy.
    Davidović SP; Nikolić SV; Curić NJ; Latinović SL; Drašković DO; Cabarkapa VS; Stošić ZZ
    Eur J Ophthalmol; 2012; 22(5):792-8. PubMed ID: 22344470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
    Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
    JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum concentration of vascular endothelial growth factor after bilateral intravitreal injection of bevacizumab.
    Wang D; Choi KS; Lee SJ
    Korean J Ophthalmol; 2014 Feb; 28(1):32-8. PubMed ID: 24505199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
    Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
    Chan WM; Lai TY; Chan KP; Li H; Liu DT; Lam DS; Pang CP
    Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
    Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
    Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
    Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
    Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological inflammatory factors as biomarkers for anatomic response in diabetic macular edema treated with anti-VEGF.
    Brito P; Costa J; Gomes N; Costa S; Correia-Pinto J; Silva R
    J Diabetes Complications; 2018 Jul; 32(7):643-649. PubMed ID: 29843962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Dabour SA
    Retina; 2013 Sep; 33(8):1623-9. PubMed ID: 23538584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
    Sheth S; Rush R; Natarajan S; Gillies M
    Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.
    Sato T; Wada K; Arahori H; Kuno N; Imoto K; Iwahashi-Shima C; Kusaka S
    Am J Ophthalmol; 2012 Feb; 153(2):327-333.e1. PubMed ID: 21930258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
    Wang X; Sawada T; Sawada O; Saishin Y; Liu P; Ohji M
    Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy.
    Sawada O; Kawamura H; Kakinoki M; Sawada T; Ohji M
    Arch Ophthalmol; 2007 Oct; 125(10):1363-6. PubMed ID: 17923544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.
    Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL
    Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes.
    Matsuyama K; Ogata N; Matsuoka M; Wada M; Nishimura T; Takahashi K
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):379-83. PubMed ID: 21810018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.